Acquired CDKN2A inactivation (gene deletion or hypermethylation resulting in decreased expression) at time of progression has been reported in studies of paired tumor analyses of other malignancies, including lymphoma, cervical cancer, and prostate cancer [19, 22, 46, 63]. This evidence concerns the gene CDKN2A and cervical carcinoma.